Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Sorafenib CAN be Co-Administered with the Following Agents, IF Administered with Caution1,2

Sorafenib CANNOT be Co-Administered with the Following Agents

  • Carboplatin and paclitaxel in combination in patients with squamous cell lung cancer1,2

Additional Important Information when Prescribing Sorafenib

Sorafenib has been shown to prolong the QT/QTc interval, which may lead to an increased risk for ventricular arrhythmias.2 Medical oncologists should be aware of the risk of co-administration of drugs that prolong the QTc interval in patients given sorafenib.3 If a drug is indicated which also prolongs the QTc interval, an ECG should be obtained 24-48 hours before and 1 week after initiating the concomitant therapy.

Pharmacists should also routinely check for concomitant use of such QT prolonging drugs such as 5HT3 antagonists, antibiotics, antifungals and over the counter drugs such as domperidone.3

Consider increasing the dose of sorafenib to 1,000 mg/ 24 hours if co-administering with rifampicin or neomycin.4,5

The international normalised ratio should be monitored during concomitant use of warfarin and sorafenib.


  1. European Medicines Agency. Sorafenib (NEXAVAR). Summary of Product Characteristics. 2015.
  2. Food and Drug Administration. Sorafenib (Nexavar) Prescribing information. 2015.
  3. van Leeuwen RW, van Gelder T, Mathijssen RH, Jansman FG. Drug-drug interactions with tyrosine-kinase inhibitors: a clinical perspective. Lancet Oncol 2014; 15: e315-326.
  4. Pajares B, Torres E, Trigo JM et al. Tyrosine kinase inhibitors and drug interactions: a review with practical recommendations. Clin Transl Oncol 2012; 14: 94-101.
  5. Teo YL, Ho HK, Chan A. Metabolism-related pharmacokinetic drug-drug interactions with tyrosine kinase inhibitors: current understanding, challenges and recommendations. Br J Clin Pharmacol 2015; 79: 241-253.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.